Medtronic (MDT) Earnings Date & Reports

Key Takeaways

• Medtronic reported Q4 revenue of $9.807 billion, up 9.9% as reported and 6.6% organically, exceeding implied guidance by 90 basis points.
• Full-year fiscal 2026 revenue reached $36.364 billion, up 8.4% as reported and 5.8% organically, marking the highest annual revenue growth in 10 years.
• Q4 non-GAAP diluted EPS was $1.55; full-year non-GAAP diluted EPS was $5.53.
• Strong performance in Cardiovascular and Diabetes portfolios drove results, with Cardiac Ablation Solutions revenue surging 78% globally.
• Company provided FY2027 guidance for 6.75% to 7.25% organic revenue growth and non-GAAP EPS of $5.90 to $6.00.
• Board approved a dividend increase to $0.72 per share for Q1 FY2027, the 49th consecutive annual increase.

Earnings Context and Why It Matters

Medtronic’s fiscal year ends in late April, making the fourth quarter and full-year results a key marker of progress for the medical technology leader. Investors closely monitor these reports for signals on portfolio momentum, particularly in high-growth areas such as pulsed-field ablation and surgical robotics, as well as overall margin trends and cash generation. With healthcare demand resilient and innovation driving share gains, the earnings provide insight into Medtronic’s ability to execute its growth strategy amid competitive pressures and macroeconomic factors.

Reported Results

Medtronic reported fourth-quarter worldwide revenue of $9.807 billion, an increase of 9.9% as reported and 6.6% on an organic basis. Non-GAAP diluted earnings per share reached $1.55. For the full fiscal year 2026, revenue totaled $36.364 billion, up 8.4% as reported and 5.8% organically. GAAP diluted EPS for the year was $3.73, while non-GAAP diluted EPS was $5.53. The company returned $4.2 billion to shareholders and generated $5.426 billion in free cash flow. Results reflected strength in Cardiovascular, particularly Cardiac Ablation Solutions, and Diabetes, with several tuck-in acquisitions completed to bolster the pipeline.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener

Market Reaction and Investor Sentiment

Shares of Medtronic reacted positively in the immediate aftermath of the June 3, 2026, release, reflecting investor approval of the revenue beat and the company’s forward guidance. Analysts highlighted the decade-high top-line growth and portfolio momentum as supportive of the valuation, while noting ongoing focus on margin expansion and integration of recent acquisitions. Sentiment heading into the report had been constructive on the back of prior-quarter beats and pipeline updates.

Forward Outlook and Key Factors to Monitor

Medtronic enters fiscal 2027 with momentum from its strongest annual revenue growth in a decade. Management guided for organic revenue growth of 6.75% to 7.25% and non-GAAP EPS in the $5.90 to $6.00 range. This outlook incorporates the benefit of a 53rd week, full-year consolidation of the Diabetes business, and impacts from tariffs and foreign currency.

Investors will track execution on key growth drivers, including Cardiac Ablation Solutions, Hugo robotic-assisted surgery, and Stealth AXiS navigation systems. Additional monitoring points include the pace of tuck-in acquisitions, such as CathWorks and the announced deals for Scientia Vascular and SPR Therapeutics, and their contribution to revenue.

Operating margins will remain a focus, given recent pressures from tariffs and one-time items. Free cash flow conversion and capital allocation, including the increased dividend, will also be watched for signs of sustained financial discipline. Pipeline milestones, such as regulatory clearances and new product launches, represent potential catalysts through the year.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.